Drug Patents owned by Sarepta Theraps Inc

1. Drug name - AMONDYS 45

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9447415 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US8524880 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Apr, 2026

(3 years from now)

US9228187 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(8 years from now)

US10287586 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(8 years from now)

CN103003430A SAREPTA THERAPS INC Antisense Molecule And Method For Treating Disease.
Oct, 2016

(5 years ago)

CN105838714A SAREPTA THERAPS INC Antisense Molecule And Method For Treating Disease.
Nov, 2030

(8 years from now)

CN105838714B SAREPTA THERAPS INC Antisense Molecules And Method For Treating Disease
Nov, 2030

(8 years from now)

IN347912B SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

IN201204202P4 SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

EP2206781A9 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781A2 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781A3 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP1766010A1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430A2 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010A4 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430A3 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2499249A1 SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

EP2499249A4 SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

EP2499249B1 SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9758783 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies Nov, 2030

(8 years from now)

US10781450 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies Nov, 2030

(8 years from now)

Drugs and Companies using CASIMERSEN ingredient

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping; treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein production; Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein production

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/2ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription

2. Drug name - EXONDYS 51

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10781451 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US9018368 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US9243245 SAREPTA THERAPS INC Means and methods for counteracting muscle disorders
Oct, 2028

(6 years from now)

CN102256606A SAREPTA THERAPS INC Method And Means Of Effectivly Hopping Human Duchenne Muscular Dystrophy Gene Exon At Least One Of 43, 46, 50-53
May, 2016

(6 years ago)

CN101896186A SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Jul, 2016

(6 years ago)

CN102264903A SAREPTA THERAPS INC Method And Means For Effectively Jumping Front Mrna Exon 45 Of Human Duchenne
Oct, 2028

(6 years from now)

CN102264903B SAREPTA THERAPS INC Method And Means For Effectively Jumping Front Mrna Exon 45 Of Human Duchenne
Oct, 2028

(6 years from now)

CN105641700B SAREPTA THERAPS INC Methods And Methods For Combating Muscular Disorders
Oct, 2028

(6 years from now)

CN105641700A SAREPTA THERAPS INC A Muscular Disorder-Resisting Mode And Method
Oct, 2028

(6 years from now)

EP2206781A2 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781A9 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781A3 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP1766010A1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430A2 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430A3 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010A4 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2203173B1 SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Oct, 2028

(6 years from now)

EP2614827A2 SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Oct, 2028

(6 years from now)

EP2614827A3 SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Oct, 2028

(6 years from now)

EP3238737A1 SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Oct, 2028

(6 years from now)

EP2614827B1 SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Oct, 2028

(6 years from now)

EP3238737B1 SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Oct, 2028

(6 years from now)

EP2203173A2 SAREPTA THERAPS INC Means And Methods For Counteracting Muscle Disorders
Oct, 2028

(6 years from now)

EP2344637B2 SAREPTA THERAPS INC Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna
Jan, 2029

(6 years from now)

EP2344637A1 SAREPTA THERAPS INC Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna
Jan, 2029

(6 years from now)

EP2344637B1 SAREPTA THERAPS INC Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna
Jan, 2029

(6 years from now)

EP2607484A1 SAREPTA THERAPS INC Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna
Jan, 2029

(6 years from now)

EP2607484B1 SAREPTA THERAPS INC Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna
Jan, 2029

(6 years from now)

EP2349287A2 SAREPTA THERAPS INC Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50- 53.
Mar, 2029

(6 years from now)

EP2349287B1 SAREPTA THERAPS INC Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50- 53.
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47751 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun, 2025

(2 years from now)

USRE48468 SAREPTA THERAPS INC Means and methods for counteracting muscle disorders Oct, 2028

(6 years from now)

USRE47769 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof Feb, 2029

(6 years from now)

US10364431 SAREPTA THERAPS INC Compositions for treating muscular dystrophy Mar, 2034

(11 years from now)

US9506058 SAREPTA THERAPS INC Compositions for treating muscular dystrophy Mar, 2034

(11 years from now)

US10337003 SAREPTA THERAPS INC Compositions for treating muscular dystrophy Mar, 2034

(11 years from now)

Drugs and Companies using ETEPLIRSEN ingredient

Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by inducing skipping of exon 51; treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by correcting a defective gene for dystrophin; treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by restoring or increasing functional dystrophin protein production; Treatment of dmd in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/2ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription
500MG/10ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription

3. Drug name - VYONDYS 53

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10421966 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US10968450 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US9024007 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US9994851 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US10227590 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

EP2206781A9 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781A2 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781A3 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP1766010A1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430A2 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010A4 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430A3 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47691 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun, 2025

(2 years from now)

US10995337 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun, 2025

(2 years from now)

US10266827 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun, 2025

(2 years from now)

Drugs and Companies using GOLODIRSEN ingredient

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/2ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.